Intact Genomics successfully exhibited at the Plant & Animal Genome Conference (PAG 33), held January 10–13, 2026, in San Diego, California. PAG is the premier international conference for agricultural genomics, bringing together scientists, researchers, and industry leaders to share the latest advances in plant and animal research.

During the conference, attendees visited Intact Genomics’ booth (#130) and met with Pawel Kosentka, Ph.D., Business Development Manager, and Chengcang Charles Wu, Ph.D., CEO. Our team showcased Intact Genomics’ innovative molecular biology reagents and solutions, including enzymes and kits for isothermal DNA/RNA amplification, simplified DNA cloning, gene editing, the largest collection of E. coli and agrobacterial competent cells, and our newly developed Direct Capture of Large DNA fragments (DCLD™) technology.

We enjoyed engaging with researchers and industry leaders from around the world and demonstrating how Intact Genomics’ products accelerate discovery in plant and animal genomics.

On October 10, 2025, our CEO, Dr. Chengcang Charles Wu was invited to speak at Washington University in St. Louis on the topic of careers outside of academia.
In his seminar, Dr. Wu shared his personal journey — from his early scientific career to starting Intact Genomics. He offered valuable insights into building a successful career in the biotechnology industry, encouraging students and researchers to explore the wide range of opportunities beyond traditional academic paths.
Dr. Wu’s talk was well received by a group of PhD candidates and faculty members in plant and microbial biosciences program. His story inspired many attendees to think broadly about how scientific innovation can translate into real-world impact in life sciences.

Intact Genomics recently exhibited at the Life Science Exhibits held at Washington University in St. Louis, where our business development team had the opportunity to connect with hundreds of researchers, scientists, and students.

During the events, we showcased our latest molecular biology reagents and innovative solutions designed to accelerate scientific discovery and support cutting-edge research. Our team engaged in insightful conversations, shared product information, and explored new collaborations with researchers working on a wide range of applications.

We are excited about the positive feedback we received and the growing interest in our products and technologies. Intact Genomics remains committed to supporting the research community with high-quality products and reliable solutions that empower scientists to achieve breakthrough results.

Stay tuned for more updates on our upcoming events and product launches!

Intact Genomics was excited to announce its participation in the 17th Annual Next Generation Dx Summit, taking place in Washington, D.C., on August 18–20, 2025. The Next Generation Dx Summit is the nexus for international thought leaders to discuss diagnostic advancement and technology innovation. This year’s event provided a valuable window on the state-of-the-art, forecasting, and future trends in point-of-care and decentralized testing, infectious disease, liquid biopsy, multi-cancer early detection, regulation, and companion diagnostics to improve the standard of care in medicine.

“Intact Genomics is a leading biotechnology firm specializing in isothermal DNA/RNA amplification, PCR, RT-qPCR, large DNA fragment cloning, and direct capture,” said Dr. Chengcang Charles Wu, the company’s CEO. “We are committed to providing high-quality products and services for the next generation of diagnostic solutions.”

Intact Genomics had a poster presentation. Click here to download our poster “Innovative FastAmp® Viral and Cell Lysis Solution Enables Simple RPA-based PoC Diagnostics and Nucleic Acids Testing of Viral Pathogens”. 

Intact Genomics (IG®) participated in the 2025 Stanford Drug Discovery Symposium, which took place April 28–29 at Stanford University. The prestigious event brought together leading researchers, biotech innovators, and pharmaceutical executives to discuss groundbreaking advancements in drug discovery and development.

Representatives from Intact Genomics, a growing leader in molecular biology reagents and point-of-care diagnostics, engaged with top scientists and industry partners during the two-day symposium. The company is showcasing its latest innovations, including its newly developed and launched Direct Capture of Large Intact Genomic DNA technologies (DCLD™ technologies), RPA kits, PEmax Enzyme, and other molecular diagnostic and gene-editing solutions designed to accelerate gene function studies and drug discovery workflows.

“Our mission is to empower researchers with the tools they need to drive scientific breakthroughs,” said Dr. Charles Wu, CEO of Intact Genomics. “Being part of the Stanford Drug Discovery Symposium is a tremendous opportunity for us to connect with the global scientific community and contribute to conversations that shape the future of medicine.”

This year’s symposium featured keynote speeches by Nobel laureates, presentations on AI in drug discovery, advances in targeted therapeutics, and panels on the future of personalized medicine. Intact Genomics’ presence highlighted its commitment to supporting innovation and collaboration across the life sciences industry.

In honor of Women’s History Month, Intact Genomics participated in a marketplace vendor show at Washington University in St. Louis on March 18, 2025. Washington University in St. Louis is one of the most prominent research universities in the US. Since 2014, Intact Genomics has provided high-quality molecular biology-related products and services for researchers at WUSTL. These resources help researchers to explore human genes and functional genomics, to better understand the causes of disease, and to advance therapeutics and diagnostic sciences.

Rosa Ye, COO of Intact Genomics, and Jennifer Gormley, VP of Business Development, attended the event and took interviews.

Women play a crucial role at Intact Genomics, contributing significantly across various departments, from operations and marketing to research and development. Their leadership, expertise, and dedication drive innovation, enhance customer engagement, strengthen our company’s growth, and help shape the future of life sciences.

In February, we welcomed our local news station for an insightful discussion on the recent NIH funding cuts and their potential impact on the scientific community.

Despite uncertainties, Intact Genomics remains committed to supporting research and pushing innovation forward. Our team is dedicated to making a difference and we are grateful for the opportunity to share our perspective.

We are thrilled to announce that Intact Genomics has been selected by the prestigious NIH SEED Company Showcase Program to participate in the Redefining Early Stage Investments (RESI) Conference 2025.

The Redefining Early Stage Investments (RESI) Conference 2025 is an important event for the life sciences sector, focusing on connecting early-stage life science companies with investors and strategic partners. The conference will take place on January 14, 2025, at the San Francisco Marriott Marquis, featuring in-person networking opportunities, followed by virtual partnering sessions from January 15-16. This event is part of the broader J.P. Morgan (JPM) Healthcare Week 2025. This week-long event is one of the largest gatherings of global healthcare leaders, including executives, investors, and innovators.

This recognition highlights Intact Genomics’ innovative work in molecular biology, drug discovery and diagnostics. The NIH SEED program supports companies whose track records demonstrate high-potential, and we are honored to be among those chosen to present our breakthroughs to a global audience of investors, industry leaders, and key stakeholders.

At the RESI Conference, Jennifer Gormley, VP of Business Development, and Dr. Chengcang Charles Wu, CEO of Intact Genomics will pitch IG®’s unique technologies including Direct Capture of Large DNA Fragments and Fungal Artificial Chromosome (FAC). We are proud to represent Intact Genomics on this important stage and look forward to engaging with potential investors and building strategic partnerships to accelerate our mission of advancing cutting-edge solutions that address critical challenges in healthcare and life sciences.

Stay tuned for updates as we gear up for this exciting event!

November 25, 2024 – Intact Genomics (IG®), a leading molecular biology reagent company, is proud to announce the launch of three new cutting-edge products tailored to enhance Recombinase Polymerase Amplification (RPA) technology. These new additions mark a significant step forward in delivering reliable, efficient, and user-friendly solutions for rapid nucleic acid detection. All IG RPA-related kits and enzymes can be in custom formats, including high concentrations, and they support lyophilization applications.

The three products include:

1. ig® Recombinase Polymerase Amplification (RPA) Kit v2
   Designed for superior accuracy, this kit offers enhanced performance in detecting low-abundance DNA and RNA sequences, ensuring reliable results even in challenging conditions.
2. FastAmp® qRPA SYBR kit
   FastAmp® qRPA SYBR Kit is a powerful tool to screen primer conditions for the lowest possible Non-template control (NTC) background.
3. FastAmp® Plant Direct RPA kit
   FastAmp® Plant Direct RPA kit offers a fast, robust method for amplifying DNA fragments from plant tissues at a single and constant temperature (37°C).

“These products exemplify our commitment to innovation and meeting the needs of our customers, ” said Charles Wu, CEO of Intact Genomics. “RPA technology has become a cornerstone in molecular diagnostics and genome research. With investment in new equipment and improvement in productivity, we also can offer more affordable high-quality products now. These new offerings aim to empower scientists with the tools they need for faster and more reliable results at lower costs.”

The launch of these products aligns with Intact Genomics’ mission to advance molecular biology solutions and underscores its role as a trusted partner in the scientific community. For more information about these products, or contact IG team at sales@intactgenomics.com.

Our CEO, Dr. Chengcang Charles Wu, attended the 16th annual Next Generation Dx Summit (https://www.nextgenerationdx.com) at the Capital Hilton in Washington D.C. where he had a post presentation and networked with other professionals and researchers to discuss important topics surrounding diagnostic advancements. Intact Genomics is a key player and contributor to novel diagnostic technology development, and we reviewed the innovative products and technologies this event featured.